Literature DB >> 7777516

Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A.

S R Bartz1, E Hohenwalter, M K Hu, D H Rich, M Malkovsky.   

Abstract

Analogs of the immunosuppressive cyclic undecapeptide cyclosporin A (CsA) with substitutions in positions 1, 4, 6, and/or 11 were rationally designed to possess substantially diminished or no immunosuppressive activity. When these compounds were assayed for their capacity to interfere with the replication of human immunodeficiency virus, some displayed a potent antiviral activity in newly infected cells. However, only CsA could interfere with virus replication in persistently infected cells. One CsA analog with antiviral activity costimulated the phytohemagglutinin-induced production of interleukin 2 by human lymphocytes. Human immunodeficiency virus particles from drug-exposed cells showed lower infectivity than virions from untreated cells. Thus, these nonimmunosuppressive analogs of CsA constitute a promising class of lead compounds to develop drugs for effective treatment of the acquired immunodeficiency syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777516      PMCID: PMC41698          DOI: 10.1073/pnas.92.12.5381

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Cyclosporine.

Authors:  B D Kahan
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

2.  The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1.

Authors:  M A Wainberg; A Dascal; N Blain; L Fitz-Gibbon; F Boulerice; K Numazaki; M Tremblay
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

3.  Inducible nuclear factor binding to the kappa B elements of the human immunodeficiency virus enhancer in T cells can be blocked by cyclosporin A in a signal-dependent manner.

Authors:  A Schmidt; L Hennighausen; U Siebenlist
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

4.  Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation.

Authors:  E A Emmel; C L Verweij; D B Durand; K M Higgins; E Lacy; G R Crabtree
Journal:  Science       Date:  1989-12-22       Impact factor: 47.728

5.  Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins.

Authors:  G Fischer; B Wittmann-Liebold; K Lang; T Kiefhaber; F X Schmid
Journal:  Nature       Date:  1989-02-02       Impact factor: 49.962

6.  Persistent human immunodeficiency virus type 1 infection of monoblastoid cells leads to accumulation of self-integrated viral DNA and to production of defective virions.

Authors:  C D Pauza; J Galindo
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Synthesis, conformation, and immunosuppressive activities of three analogues of cyclosporin A modified in the 1-position.

Authors:  J D Aebi; D T Deyo; C Q Sun; D Guillaume; B Dunlap; D H Rich
Journal:  J Med Chem       Date:  1990-03       Impact factor: 7.446

8.  Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells.

Authors:  P Fisch; M Malkovsky; S Kovats; E Sturm; E Braakman; B S Klein; S D Voss; L W Morrissey; R DeMars; W J Welch
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

9.  Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog.

Authors:  B Rosenwirth; A Billich; R Datema; P Donatsch; F Hammerschmid; R Harrison; P Hiestand; H Jaksche; P Mayer; P Peichl
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

10.  The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes.

Authors:  P S Mattila; K S Ullman; S Fiering; E A Emmel; M McCutcheon; G R Crabtree; L A Herzenberg
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  24 in total

1.  Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections.

Authors:  M Wallace; A M Scharko; C D Pauza; P Fisch; K Imaoka; S Kawabata; K Fujihashi; H Kiyono; Y Tanaka; B R Bloom; M Malkovsky
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  Nef enhances HIV-1 infectivity via association with the virus assembly complex.

Authors:  Mingli Qi; Christopher Aiken
Journal:  Virology       Date:  2008-01-14       Impact factor: 3.616

3.  The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein.

Authors:  D Braaten; H Ansari; J Luban
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum.

Authors:  M E Perkins; T W Wu; S M Le Blancq
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes.

Authors:  B Sherry; G Zybarth; M Alfano; L Dubrovsky; R Mitchell; D Rich; P Ulrich; R Bucala; A Cerami; M Bukrinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

6.  Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.

Authors:  Theodora Hatziioannou; David Perez-Caballero; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins.

Authors:  C Aberham; S Weber; W Phares
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy.

Authors:  Emily K Cartwright; Lori Spicer; S Abigail Smith; David Lee; Randy Fast; Sara Paganini; Benton O Lawson; Melon Nega; Kirk Easley; Joern E Schmitz; Steven E Bosinger; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Jacob D Estes; Jeffrey D Lifson; Cynthia A Derdeyn; Guido Silvestri
Journal:  Immunity       Date:  2016-09-20       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.